Zacks Research upgraded shares of LifeMD (NASDAQ:LFMD – Free Report) from a strong sell rating to a hold rating in a report published on Monday,Zacks.com reports.
A number of other analysts have also recently issued reports on LFMD. Mizuho set a $7.00 target price on LifeMD in a research report on Thursday, August 6th. BTIG Research cut their price target on LifeMD from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. UBS Group reaffirmed a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. HC Wainwright reduced their price objective on LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of LifeMD in a report on Tuesday, August 4th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $7.57.
Read Our Latest Stock Analysis on LifeMD
LifeMD Price Performance
LifeMD (NASDAQ:LFMD – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The company had revenue of $47.28 million during the quarter, compared to analyst estimates of $49.16 million. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. As a group, equities analysts expect that LifeMD will post -0.48 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of LFMD. Tower Research Capital LLC TRC lifted its holdings in shares of LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after purchasing an additional 2,452 shares during the period. Quarry LP acquired a new position in LifeMD in the 3rd quarter valued at $52,000. Legal & General Group Plc raised its position in LifeMD by 187.4% during the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after buying an additional 6,614 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in LifeMD during the 4th quarter worth $36,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of LifeMD in the 2nd quarter worth $153,000. Institutional investors and hedge funds own 35.52% of the company’s stock.
About LifeMD
LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.
LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.
Recommended Stories
- Five stocks we like better than LifeMD
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.
